INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 04 2025
0mins
Should l Buy ?
Source: Globenewswire
Clinical Trial Success: INmune Bio's Phase I/II trial of INKmune™ for metastatic castration-resistant prostate cancer has successfully met its primary and secondary endpoints, demonstrating safety and efficacy in activating NK cells in patients.
Future Developments: Following the trial's success, INmune Bio plans to initiate a randomized Phase 2b trial targeting patients with less severe disease to further evaluate the drug's effects and potential clinical benefits.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
